Merck & Co. Stock Rises on Raised Guidance and Upbeat Earnings
Merck & Co.'s stock price rose on September 2, 2026, as the company raised its full-year sales guidance following a Q2 2026 revenue increase of 5 percent.
The pharmaceutical giant's share price traded at $150.78 USD on the New York Stock Exchange, close to its recent 52-week high of $156.92 USD and giving it a market capitalization of $369.73 billion USD.
Merck & Co.'s Q2 2026 sales growth led to an updated full-year outlook, with the company now expecting revenue between $66.3 billion USD and $67.3 billion USD, up from its previous guidance of $65.8 billion USD to $67.0 billion USD.
The analyst consensus rating remains a Moderate Buy, with a price target of $147.60 USD per share, which is modestly below the recent opening price of $151.85 USD.